The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis

Implementation Science

Volumn 5, Issue 1, 2010, Pages

  Ibargoyen Roteta, Nora ^a   Gutiérrez Ibarluzea, Iñaki ^a   Rico Iturrioz, Rosa ^a   López Argumedo, Marta ^a   Reviriego Rodrigo, Eva ^a   Cabriada Nuño, Jose L ^b   Schünemann, Holger J ^c  

^a Basque Office for Health Technology Assessment (Osteba)   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953525952     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-5-48     Document Type: Article

References (42)

1. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Kikuch K, Saniabadi AR. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70(1):36-44. 10.1159/000080079, 15297776.
2. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 2007, 39(5):430-434. 10.1016/j.dld.2007.01.001, 17379588.
3. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjamasson I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective uncontrolled study. Clin Gastroenterol Hepatol 2003, 1:28-35. 10.1053/jcgh.2003.50005, 15017514.
4. Hanai H, Iida T, Watanabe F, Yamada M, Takeuchi K, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Saniabadi AR. Intensive granulocyte and monocyte apheresis versus intravenous prednisolone in patients with severe ulcerative colitis: a multicentre randomised conrolled study [abstract]. Gut 2006, 55(Suppl 2):A1. 1859999, 16531518.
5. Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Fukagawa M, Umezu M, Abe T, Kasuga M. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005, 20(10):1567-1571. 10.1111/j.1440-1746.2005.03907.x, 16174075.
6. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsumoto K. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective pilot study. Aliment Pharmacol Ther 2004, 20(7):783-792. 10.1111/j.1365-2036.2004.02189.x, 15379839.
7. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991, 86:489-493. 1554212, 1684141.
8. Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006, 12(Suppl 1):S10-S14. 10.1097/01.MIB.0000195386.19268.b3, 16378005.
9. Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol 2008, 43:51-56. 10.1007/s00535-007-2129-6, 18297436.
10. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005, 100(6):1362-1369. 10.1111/j.1572-0241.2005.41089.x, 15929771.
11. Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Cabriada-Nuño JL, Clofent-Vilaplana J, Ginard-Vicens D, Domènech-Morral E, Oliva-Oliva G, Queiro-Verdes T. Establecimiento de Estándares, registro y análisis de casos de tratamiento de la colitis ulcerosa mediante sistemas de aféresis. Informes de Evaluación de Tecnologías Sanitarias 2006, Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluaciòn de Tecnologías Sanitarioas del País Vasco, OSTEBA N° 2006/5.
12. Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007, 26:779-794.
13. Scottish Intercollegiate Guidelines Network: A guidelines developers' handbook. , http://www.sign.ac.uk/guidelines/fulltext/50/index.html
14. Centre for Evidence-Based Medicine de Oxford. Levels of Evidence and Grades of Recommendation. , http://www.cebm.net/index.aspx?o=1025
15. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O'Connell D, Oxman AD, Phillips B, Schünemann H, Edejer TT, Vist GE, Williams JW, . The GRADE working group Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004, 4(1):38. 10.1186/1472-6963-4-38, 545647, 15615589, The GRADE working group.
16. Schünemann HJ, Best D, Vist G, Oxman AD. Letters, numbers symbols and words: how to communicate grades of evidence and recommendations. CMAJ 2003, 169(7):677-680. 202287, 14517128.
17. Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA, Manthous CA, Maurer JR, McNicholas WT, Oxman AD, Rubenfeld G, Turino GM, Guyatt G, . ATS Documents Development and Implementation Committee An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006, 174(5):605-614. 10.1164/rccm.200602-197ST, 16931644, ATS Documents Development and Implementation Committee.
18. Guyat GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ, . GRADE Working Group Going from evidence to recommendations. BMJ 2008, 336(7652):1049-1051. 10.1136/bmj.39493.646875.AE, 18467413, GRADE Working Group.
19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, . GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336(7650):924-926. 10.1136/bmj.39489.470347.AD, 18436948, GRADE Working Group.
20. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, . for the GRADE Working Group What is 'quality of evidence' and why is it important to clinicians?. BMJ 2008, 336(7651):995-998. 10.1136/bmj.39490.551019.BE, 18456631, for the GRADE Working Group.
21. Schünemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, Wisløff TF, Del Mar C, Hayden F, Uyeki TM, Farrar J, Yazdanpanah Y, Zucker H, Beigel J, Chotpitayasunondh T, Hien TT, Ozbay B, Sugaya N, Oxman D. Transparent development of the WHO rapid advice guidelines. PLoS Med 2007, 4(5):e119. 10.1371/journal.pmed.0040119, 1877972, 17535099.
22. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, . GRADE Working Group Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336(7653):1106-1110. 10.1136/bmj.39500.677199.AE, 18483053, GRADE Working Group.
23. Cabriada-Nuño JL, Domènech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. Documento Consenso en el uso de la granulocitoaféresis en pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2006, 29:85-91. 10.1157/13083905, 16448611.
24. Índice de actividad de la colitis ulcerosa: Índice Clínica Mayo. , http://www.ghcontinuada.com/cgi-bin/wdbcgi.exe/gh/utiles.colitis_mayoclinic
25. Gutiérrez-Ibarluzea I, Arcelay A. Leucocitoaféresis para el tratamiento de la enfermedad inflamatoria intestinal. Informe de Revisión. Vitoria-Gasteiz. Departamento de Sanidad Gobierno Vasco 2004. Informe n° Osteba IR-04-03
26. GRADEpro [Computer program]. Version 3.2 for Windows 2008, Jan Brozek, Andrew Oxman, Holger Schünemann, GRADEpro.
27. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, . Adacolumn Study Group A randomized double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135(2):400-409. 10.1053/j.gastro.2008.04.023, 18602921, Adacolumn Study Group.
28. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults with Ulcerative Colitis. Gastroenterology 2007, 132(2):763-786. 10.1053/j.gastro.2006.12.038, 17258735.
29. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003, 9(4):307-321. 10.2174/1381612033391928, 12570823.
30. Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective?. Dig Liver Dis 2007, 39(7):617-625. 10.1016/j.dld.2007.03.007, 17531555.
31. Jo Y, Matsumoto T, Mibu R, Iida M. Addition of leukocytapheress to steroid therapy: is it beneficial in recurrence of moderate-to severe ulcerative colitis?. Dis Colon Rectum 2003, 46(10 Suppl):S3-9.
32. Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panes J. Evaluation of 5 versus 10 granulocytapheresis sessions in steroid-dependent ulcerative colitis: A pilot prospective, multicenter randomized study. World J Gatroenterol 2007, 13(15):2193-2197.
33. Cabriada-Nuño J, Bernal-Martínez A, Hernández-Martín A, Arévalo-Serna J, Fernández-Prado E. Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente. Dial Traspl 2007, 28(2):47-55.
34. Johnson FR, Özdemir S, Mansfield C, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's Disease Patients' Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology 2007, 133(3):769-779. 10.1053/j.gastro.2007.04.075, 17628557.
35. Atkins D, Briss PA, Eccles M, S Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N, Mason J, O'Connell D, Oxman AD, Phillips B, Schünemann H, Edejer TT, Vist GE, Williams JW, . The GRADE Working Group Systems for grading the quality of evidence and the streght of recommendations II: Pilot study of a new system. BMC Health Serc Res 2005, 5(1):25. The GRADE Working Group.
36. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, Vist GE, Schünemann HJ, . for the GRADE working group Incorporating considerations of resources use into grading recommendations. BMJ 2008, 336(7654):1170-1173. 10.1136/bmj.39504.506319.80, 18497416, for the GRADE working group.
37. Calderón C, Rotaeche R, Etxebarria A, Marzo M, Rico R, Barandiaran M. Gaining insight into the Clinical Practice Guideline development processes: qualitative study in a workshop to implement the GRADE proposal in Spain. BMC Health Serv Res 2006, 6:138. 10.1186/1472-6963-6-138, 1626459, 17059600.
38. Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA, . Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) Granulocyte apheresis in steroid-dependent inflammatory bowel disease: a prospective open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352. 10.1111/j.1365-2036.2004.02288.x, 15606397, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
39. Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12 month follow-up study. Int J Colorectal Dis 2006, 21:493-504. 10.1007/s00384-005-0069-2, 16538495.
40. Efficacy Study of Granulocytapheresis Plus steroids vs Steroids alone in active steroid dependent ulcerative colitis (ATICCA). , http://clinicaltrials.gov/ct2/show/NCT00702611
41. Stange EF, Travis S, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF, . for the European Crohn's and Colitis Organisation (ECCO) European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. JCC 2008, 2:1-23. for the European Crohn's and Colitis Organisation (ECCO).
42. Abreu MT, Plevy S, Sands BE, Weinstein R. Selective Leukocyte Apheresis for the Treatment of Inflammatory Bowel disease. J Clin Gastroenterol 2008, 41(10):874-888.